2 Behbahan Faculty of Medical Sciences, Behbahan, Iran

Disclosures: Yazhou Chen: Nothing to Disclose, Benjamin Laevens: Nothing to Disclose, Teresa Lemainque: Nothing to Disclose, Gustav Mller-Franzes: Nothing to Disclose, Tobias Seibel: Nothing to Disclose, Carola Dlugosch: Nothing to Disclose, Jan Clusmann: Nothing to Disclose, Paul-Henry Koop: Nothing to Disclose, Thriveni Raju: Nothing to Disclose, Niharika Jakhar: Nothing to Disclose, Rongpeng Gong: Nothing to Disclose, Simon Schophaus: Nothing to Disclose, Kai Markus Schneider: Nothing to Disclose, Daniel Truhn: Nothing to Disclose, Carolin Victoria Schneider: Nothing to Disclose 848 METASIGHT'S METABOLIC DYSFUNCTION-ASSOCIATED STEATOHEPATITIS (MASH)-FIBROSIS SCORE: A BLOOD TEST ENABLING PATIENT MONITORING OF LIVER FIBROSIS Shira Shaham-Niv 1 Eldad Kepten 1 Boris Sarvin 1 Mark Vernik 1 Ilya Podolsky 1 Carmel Shor 1 Claudia Filozof 2 Tomer Shlomi 1 Jerry Colca 3 Arun Sanyal 4 , 1 MetaSight Diagnostics, 2 Fortrea, 3 Western Michigan University, 4 Virginia Commonwealth University Background: Non- invasive diagnosis of MASH-fibrosis and monitoring of disease progression are of major clinical need, emphasized by the recent approval of a first MASH drug

But a 10mg retatrutide vial at a 1-2mg starting dose will need multiple needle insertions over several weeks
The fertilized eggs that had developed to the 2-cell stage were transferred into the oviducts of pseudopregnant ICR females, and newborns were obtained